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Objectives:Upon completion of this article, the reader will be
able to describe the underlying mechanism of various abla-
tion techniques, including percutaneous chemical ablation,
irreversible electroporation, high-intensity–focused ultra-
sound ablation, laser ablation, microwave ablation, radio-
frequency ablation, and cryoablation, as well as the clinical
outcomes in the management of patients with primary and
secondary liver tumors.
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Percutaneous Chemical Ablation
Percutaneous chemical ablation is a relatively safe and effec-
tive procedure used in the treatment of small hepatocellular
carcinoma (HCC). It is well tolerated by patients and has very
low reported major and minor complication rates (2%).1,2
Although the technique requires adequate expertise in plac-
ing the needle with imaging guidance, the procedure is















Abstract Tumor ablation is a minimally invasive technique used to deliver chemical, thermal,
electrical, or ultrasonic damage to a specific focal tumor in an attempt to achieve
substantial tumor destruction or complete eradication. As the technology continues to
advance, several image-guided tumor ablations have emerged to effectively manage
primary and secondary malignancies in the liver. Percutaneous chemical ablation is one
of the oldest and most established techniques for treating small hepatocellular
carcinomas. However, this technique has been largely replaced by newer modalities
including radiofrequency ablation, microwave ablation, laser-induced interstitial ther-
motherapy, cryoablation, high-intensity–focused ultrasound ablation, and irreversible
electroporation. Because there exist significant differences in underlying technological
bases, understanding each mechanism of action is essential for achieving desirable
outcomes. In this article, the authors review the current state of each ablation method
including technological and clinical considerations.
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except multi–side-hole needle if one chooses. Chemical
agents for percutaneous ablation include ethanol, acetic
acid, and sodium hydroxide.2 Percutaneous ethanol injection
(PEI) is well established and the most commonly used chemi-
cal ablation technique. It was shown that PEI can safely
achieve complete necrosis of small HCCs, and achieve 5-
year survival rates of 32 to 38% in nonrandomized trials in
the 1990s.3–5However, due tomultiple session numbers, high
local tumor progression rate, and variable ablation zone in PEI
compared with radiofrequency (RF) ablation, the use of PEI is
now limited to situations when RF ablation should not be
performed, such as when the tumor is in close proximity to
large vessels or critical organs.1,6–8 In one study evaluating
the treatment of small HCC, RF ablation demonstrated an
approximately 20% higher survival rate at 3 to 4 years and
fewer treatment sessions than PEI in three randomized
controlled trials.9–11 It has been confirmed again in recent
meta-analyses evaluating these randomized controlled trials
that RF ablation is better than PEI in the treatment of small
HCC.12,13
The basic mechanism of action of ethanol is through
cytoplasmic dehydration, denaturation of cellular proteins,
and microvascular thrombosis. These changes eventually
result in coagulation necrosis of tumor tissue.2,14 For a
chemical agent to exert its cytotoxic effect, it must be trans-
ported from the point of injection through the interstitial
space into the cytoplasmic compartment of the tumor. This is
primarily accomplished through two mechanisms: diffusion
and convection. Chemical agents with a relatively low mo-
lecular weight, such as ethanol and acetic acid, are trans-
ported mainly by diffusion and rely on the concentration
gradient between two compartments.15 Direct injection of a
high-concentration agent using a multi–side-hole needle
placed into a tumor at multiple sites will not only increase
the interstitial pressure but also establish amuch higher local
concentration gradient, resulting in high convective and
diffusive flux of the agent into the cytoplasm. Factors associ-
ated with homogeneous diffusion of ethanol include soft and
small (< 3 cm) hepatic tumors with fewer septations or
daughter nodules.2While ethanol is incapable of penetrating
the septae, acetic acid has an advantage of dissolving lipids
and infiltrating the septae and tumor capsules.16 As a result,
the total injected volume and the number of treatment
sessions with acetic acid are less than those with ethanol
to achieve the same cytotoxic effect. The typical volume of
acetic acid needed for each treatment session is approxi-
mately one-third the volume used for ethanol ablation based
on earlier observations of animal study and clinical
experiences.17,18
One other chemical agent that has been used is sodium
hydroxide. Sodium hydroxide has been studied in an animal
model that demonstrated that sodium hydroxide has a con-
centration-dependent necrotizing effect with less systemic
toxicity.19When acetic acid and sodium hydroxide are mixed
together, an exothermic neutralization reaction occurs. Exo-
thermic neutralization is a chemical reaction between an acid
and a base in which heat, salt, and water are produced. In a
recent study, Farnam et al injected acetic acid and sodium
hydroxide simultaneously into an ex vivo porcine liver to
investigate the exothermic neutralization reaction for poten-
tial use in tissue ablation.20 The authors confirmed that the
reaction between the two reagents released a significant
amount of heat energy at the site of injection and created
histologic changes consistent with coagulation necrosis. A
high concentration and volume of acetic acid and sodium
hydroxide correlated with higher temperatures and larger
areas of gross pathologic changes.
Irreversible Electroporation
Percutaneous irreversible electroporation (IRE) is a nonther-
mal ablative technique in which short (microsecond to milli-
second) pulses of high voltage electrical energy are applied to
a targeted tissue through electrodes.21 Ninety pulses of 1,000
to 3,000 V/cm direct current energy are delivered to generate
destabilizing electrical potential across the cell membrane,
resulting in the formation of permanent nanopores in the
lipid bilayer. This irreversible disruption and increased per-
meability of the cell membrane is the key mechanism for cell
death.22–24
Electroporation is a dynamic phenomenon that can cause
either reversible or irreversible damage, depending on the
transmembrane electric voltage to the cell membrane. If the
cells are located within areas where the electric field magni-
tude is greater than the threshold, reversible electroporation
occurs in the cell membranes. If the voltage surpasses a
second threshold, it creates irreversible and persistent pores
in the cell membrane that induce cell death.25
IRE has been investigated by Edd et al in an animal model
to analyze the efficacy as an independent tissue ablation
method.24 In perfusion-fixed animal livers, the authors ob-
served microvascular occlusion, endothelial cell necrosis, and
diapedeses, resulting in ischemic damage to the parenchyma
and massive accumulation of erythrocytes in sinusoids ap-
proximately 3 hours after electroporation. However, the
integrity of vascular structures around the treated site was
preserved in this study.
The finding of preserved blood vessels at the margin of
ablated tissue was again observed in a study with porcine
liver by Rubinsky et al21 in 2007. These authors hypothesized
that the vessel-preserving effect of IRE is likely caused by a
higher proportion of collagenous connective tissue and elas-
tic fiber, as well as the lack of a normal cellular membrane in
the vessel wall. This is supported by the finding of mild
inflammatory change in the vessels located in the ablated
zone.
In a recent study using Yorkshire pig livers, Lee et al
demonstrated that IRE is a safe and effective ablative
method, inducing complete tissue death via apoptosis
while fully preserving the periablative zone structures
including blood vessels, bile ducts, and surrounding normal
tissues.26 This finding is explained by the presence of gap
junctions of the smooth muscle cells, in addition to higher
contents of collagenous and elastic fibrous tissue in both
bile ducts and blood vessels. Gap junctions are the distinc-
tive cellular structure of the smooth muscle cells that may
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act as a barrier preventing the electrical current from
traveling through the junction between cells, thereby the
integrity of the smooth muscle cell membrane is not dis-
rupted or changed. Hence, the bile ducts and vessels around
the ablated zone are preserved.
This advantage of IREwith lackof a heat-sink effect enables
better tumor ablationwith less risk of damage to the adjacent
vessels, ducts, or critical organs comparedwith other thermal
ablation techniques including RF ablation, microwave (MW)
ablation, and cryoablation. For this reason, interest in IRE
application is increasing, especially for use in the pancreas or
liver where vital structures and ducts can easily be damaged
by thermal ablation methods.
The safety of IRE for tumor ablation in humans was first
reported by Thomson et al27 in a single-center nonrandom-
ized cohort study in 2011. In the 38 patients with advanced
malignant tumors in the liver, kidney, or lung, a total of 69 IRE
ablations were performed with no mortalities at 30 days.
Complete ablation was achieved in 66% of tumors; most
treatment failures occurred in renal and lung tumors. Adverse
events directly related to electroporation included cardiac
dysrhythmias and obstruction of the upper ureter. Though
there was one unintentional ablation of the adrenal gland,
therewas no other evidence of adjacent organ damage related
to the IRE. Owing to transient ventricular arrhythmia occur-
ring in four patients, ECG-synchronized delivery was used
subsequently in the remaining patients. The authors conclud-
ed that IRE is safe for human clinical application when
adequate ECG synchronization is used.
Narayanan et al reported on the feasibility and clinical
safety of computed tomography–guided percutaneous IRE in
14 patients with unresectable locally advanced pancreatic
cancer.28 The percutaneous pancreatic IRE procedure was
well tolerated with a low complication rate. Complications
included spontaneous pneumothorax and pancreatitis that
were self-limited and completely reversible; there were no
deaths related to the procedure.
The safety and efficacy of percutaneous IRE ablation for
hepatic tumors located centrally or close to the major bile
ducts, portal pedicles, or hepatic veins has been evaluated in
several studies.29–31 Kingham et al tested the safety of IRE for
treating hepatic tumors located within 1 cm from major
hepatic veins or major portal pedicles.29 In this study, they
reported complications including cardiac arrhythmia and
portal vein thrombosis. However, the overall morbidity was
only 3% with no treatment-associated mortalities. Cannon et
al also examined the safety and early efficacy of IRE for
hepatic malignancies in proximity to vital structures.31 A
total of 48 procedures were performed in 44 patients with
centrally located tumors in proximity to major vascular/
biliary structures or adjacent organs. Technical success was
achieved in 100%, and five patients had nine transient adverse
events with complete resolution within 30 days. In a retro-
spective study, Silk et al suggested that IRE may be an option
for centrally located peribiliary hepatic tumors.30 Although
these studies demonstrated the safety of IRE, larger studies
and longer follow-up are necessary to determine long-term
efficacy.
High-Intensity–Focused Ultrasound Ablation
High-intensity–focused ultrasound ablation (HIFU) is one of
the thermal ablation therapies using high temperature to
treat a targeted lesion. It is a noninvasive therapeutic modali-
ty, in which focused acoustic energy is precisely delivered
from an extracorporeal source to the focal zone. This high-
intensity–focused energy is then converted to heat, which
destroys diseased tissues without damaging overlying and
surrounding normal structures.
A high-frequency ultrasound beam (0.5–10 MHz) is gen-
erated by a therapeutic ultrasound transducer and arranged
into a spherical form by an acoustic lens to create a small and
discrete focal point. As the beam approaches the focal point,
the power density of the converging ultrasound increases and
the energy is accumulated at the focal zone. This phenome-
non subsequently induces coagulation necrosis of the tar-
geted lesion by creating acoustic cavitation and elevating
tissue temperature to above 60°C.32,33 Temperatures can
rise from 65 to 85°C; however, higher temperatures are
avoided to prevent boiling of liquids inside the tissue.
HIFU technology was first described by Lynn et al34 in
1942. These authors designed an efficient generator of fo-
cused ultrasound that was successfully operated to produce
focal heating in the center of the liver tissue with minimal
effects at the surface and no effects on the intervening tissue.
In animals, high-intensity focal ultrasound produced local
cerebral changes through intervening scalp, skull, and me-
ninges. Since its first introduction in 1942, the technology of
HIFU has continuously evolved, and recent developments
have allowed its application to treat tumors of various solid
organs, including the pancreas, liver, prostate, breast, uterus,
bone, and soft tissue.35–38
Recently, the addition of magnetic resonance (MR) guid-
ance for HIFU has generated a renewed interest in this
technology for tumor ablation. MR imaging–guided HIFU or
focused ultrasound is mainly used in the treatment of uterine
fibroids for which it has been approved for use by the U.S.
Food and Drug Administration (FDA). It is, however, being
tested to determine its clinical application for other benign
and malignant tumors of the breast, prostate, liver, and
uterus.39,40
In the liver, the utility of HIFU has been examined in the
treatment of unresectable HCC or metastases. Despite the
challenges of targeting within the liver due to respiratory
motion, HIFU has been shown to be safe and effective. Xu et al
reported their experience in treating 145 patients in whom
symptoms were relieved in 84.4% and tumor size was de-
creased by various degrees.41 The 2-year overall survival rate
was dependent on tumor stages. HIFU has also been shown to
be safe in treating liver tumors located in close proximity to
major vessels. In a study by Zhang et al,42 39 patients with
HCCwere treatedwith HIFU and therewas no evidence of any
major blood vessel injury when treating tumors located less
than 1 cm from the inferior vena cava (IVC), main hepatic
vein, or portal vein.
In a single-center study, Ng et al reported that HIFU, when
used as the primary therapy, achieved an overall effectiveness
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rate of 79.5% in 49 patients with unresectable HCC.32 When
the total number of ablated tumors is considered, a complete
ablation rate reaches 91% for small HCC (3 cm). The 1- and 3-
year overall survival rates were 87.7 and 62.4%, respectively.
Child-Pugh liver function grading was the most significant
prognostic factor influencing the overall survival rate. The
authors concluded that HIFU is an effective modality in the
treatment of unresectable HCC, with a high technique effec-
tiveness rate and favorable survival outcomes.
Because the ultimate goal for liver ablation is to improve
the overall survival of the patient, it is critical when assessing
new technologies that survival data be examined. In a recent
study, Cheung et al compared survival rates between patients
with small HCC (3 cm) treated with HIFU and RFA.43 In this
study, the 1- and 3-year overall survival rates of HIFU and RF
ablation groupswere 97.4 versus 94.6% and 81.2 versus 79.8%,
respectively (p ¼ 0.530). The corresponding 1- and 3-year
disease-free survival rates were 63.6 versus 62.4% and 25.9
versus 34.1%, respectively (p ¼ 0.683). The authors concluded
that in the treatment of small HCC, HIFU provides outcomes
comparable to that of RF ablation.
Transarterial chemoembolization (TACE) has been com-
bined with thermal ablation therapies in an attempt to
achieve more complete necrosis of HCC. Because TACE may
reduce blood flow of a tumor, heat loss caused by adjacent
vessels may be reduced.44 Likewise, HIFU has been used in
conjunction with TACE and a randomized clinical trial has
shown a significant survival benefit in the group with TACE
and HIFU compared with the TACE-only group.45 Jin et al
reported a similar experience of HIFU and TACE in patients
with unresectable HCC.46 This study demonstrated that 45.2%
of patients achieved complete tumor ablationwhenTACEwas
combined with HIFU. Ablation response and tumor size were
major prognostic factors.
Other indications for HIFU have been investigated in
animal studies by Vaezy et al and Noble et al.47,48 Namely,
HIFU has been tested in the treatment of a variety of benign
splenic conditions. Specifically, HIFU has been found to be
effective in achieving hemostasis in hemorrhagic spleen
models with no apparent harmful effects to the spleen.
Another recent experimental study demonstrated HIFU to
be feasible and effective for treating splenomegaly and hyper-
splenism.49 Zhu et al also reported the efficacy and safety of
HIFU in patients with HCC and hypersplenism.38 After HIFU
treatment, mean splenic ablation of approximately 28% was
achieved and the white blood cell count, platelet count, and
liver function were improved.
Laser Ablation
Percutaneous laser ablation is a hyperthermia-based tech-
nique that destroys targeted tissues by using heat energy
converted from absorbed light. Laser light is transmitted to
the lesion via bare-tip quartz fibers with diameter of 300 to
600 µm inserted through multiple small-caliber needles (21
gauges). Inside the tissue, laser light travels for a short
distance (12–15 mm) as a result of scattering, reflection,
and absorption.50 The absorbed light energy is then evenly
distributed (mainly by scattering) and is converted to heat
that is further spread by conduction, creating a large area of
coagulation necrosis.51–53Using 21-gauge needles for placing
multiplefibers is considered less traumatic comparedwith 7F
or 9F single cannulation needles in patients with liver cirrho-
sis who have higher risk of bleeding.54
Because of its optimal penetration depth into surrounding
tissues, since thefirst introduction of phototherapy in tumors
in 1983, Nd:YAG (neodymium:yttrium aluminum garnet)
lasers (wavelength, 1,064 nm) have been widely used in the
treatment of various liver malignancies.55,56 The optimal
penetration of laser light is directly associated with a lower
temperature gradient throughout the ablation zone, less risk
of carbonization and vaporization of tissue, and better treat-
ment results for tumors.57 The penetration depth of laser
light is greater in metastatic tumors than in normal liver
tissue, and coagulation necrosis results in reduced penetra-
tion by approximately 20% in both tissues.57,58 A single bare-
tip fiber can create a spherical ablation zone with a diameter
of 12 to 16 mm.59 When multiple fibers are arranged in the
tumor, the area of ablation can be significantly increased.
In a single-center study, Pacella et al first reported that laser
ablation is a highly effective therapeutic modality in patients
with HCC smaller than 4 cm.60 The study, involving 82 patients
with 99 lesions, demonstrated a complete tumor ablation rate
of 90.9%. The safety of the procedure was investigated by
Arienti et al in a largermulticenter study involvingnine centers
in Italy with 520 patients who underwent 1,004 treatment
sessions for 647 HCC nodules.61 There were four (0.8%) deaths
and 15 (1.5%)major complicationswithout any tumor seeding.
Major complications were associated with excess energy de-
position and high-risk locations. Sixty-two (6.2%) sessions
resulted inminor complications associatedwith excess energy,
high bilirubin level, and low prothrombin time. Complete
necrosis was achieved in 60% of all HCCs, and in 81.1% of small
nodules ( 3 cm). The authors concluded that the procedure is
safe in the treatment of small HCCs. In a separate retrospective
study evaluating 87 patients with 180 liver metastases from
colorectal carcinoma, Puls et al reported a technical success
rate of 99%, an effectiveness rate of 85.6% on follow-up after 24
to 48 hours, and a local tumor progression rate of 10% after
6months.62Median survival timewas 54months and survival
rates were 95.7% at 1 year, 86.2% at 2 years, 72.4% at 3 years,
50.1% at 4 years, and 33.4% at 5 years.
As laser ablation is increasingly being used in the treat-
ment of liver malignancies including HCC andmetastases, the
technology is being compared with RF ablation in an attempt
to validate its technical reliability and efficacy.59 Recently,
Orlacchio et al compared the two ablation technologies in the
treatment of HCC smaller than 4 cm in patients with liver
cirrhosis.63 Thirty patients with single HCC  4 cm in diam-
eter were randomly assigned to one of two treatments and
followed up for up to 12 months. Complete response rates
with laser and RF ablations were 87 and 93%, respectively;
this finding was not statistically significant. There were also
no differences in the overall local recurrence-free survival
rates between the two groups; however, patients treatedwith
laser ablation did showahigher recurrence rate for HCC larger
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than 2 cm (p ¼ 0.0081), and tumor necrosis factor-α with
postablation syndromewas found to be significantly higher in
the RF ablation group (p < 0.05). Overall, in this study, RF
ablation appears more effective comparedwith laser ablation
for treating larger HCCs. However, laser ablation can be
considered an alternative treatment option for tumors
smaller than 2 cm for its lower complications rates.
Laser ablationmayalso be combinedwith othermodalities
to achieve an increased volume of tumor necrosis. In an
animal study, Zou et al investigated the effects of laser
ablation combined with PEI on rabbit VX2 liver tumors.64
VX2 tumors in the liver of 80 rabbits were randomly separat-
ed into four groups; each group was treated with laser
ablation alone, PEI alone, laser ablation immediately followed
by PEI, or PEI immediately followed by laser ablation. The
study demonstrated that combined therapy with PEI imme-
diately followed by laser ablation resulted in a significantly
larger volume of coagulation necrosis with reduced residual
tumor volume. It was hypothesized that tissue destruction by
ethanol may have resulted in increased thermal conduction.
In addition, PEI is associated with a sclerosing effect on blood
vessels, thus reducing the heat-sink effect and enhancing the
effect of the laser ablation.
Microwave Ablation
In MW ablation, the mechanism of heat generation is based
on rapid frictional movement of water molecules in the high-
frequency (900–2,500 MHz) electromagnetic field. An oscil-
lating electromagnetic field around the antenna forces water
molecules to continuously realign, resulting in high kinetic
energy that is converted to heat in the tissue.11,65,66
MW ablation has several advantages, including greater
penetration of energy into tissue (resulting in a larger area of
ablation), less susceptibility to convective heat-sink effect
from surrounding vessels, higher intratumoral temperatures,
faster ablation times, and simultaneous activation of multiple
antennae.66–69 In addition, MW ablation does not require
grounding pads or other ancillary devices. Even in tissues
with high impedance, such as lung or charred and desiccated
tissues, MW can be used effectively due to its low sensitivity
to local variation in tissue physical properties. The incidence
and severity of postablation syndrome (flu-like illness, low-
grade fever, nausea, and/or vomiting) is found to be similar to
that reported for RF ablation. Postprocedural pain for MW
ablation is correlated with total ablation volume.70
The safety, effectiveness, and survival rates have been
reported in several studies with MW ablation in the treat-
ment of HCC. In a cohort study with 234 patients who
underwent MW ablation, Dong et al showed a complete
ablation rate of 89%, local recurrence rate of 7%, and cumula-
tive survival rates at 1, 2, 3, 4, and 5 years of 92.7, 81.6, 72.9,
66.4, and 56.7%, respectively.71 In a retrospective study of 102
patients with HCC, Lu et al reported that MWablation and RF
ablation are both effective in treating HCC. The local tumor
control, complications related to treatment, and long-term
survivals were equivalent for the two modalities72; complete
tumor ablation rates with MWablation and RF ablation were
94.9 and 93.1%, respectively. The local recurrence rate was
11.8% for MWablation versus 20.9% for RF ablation, and there
was no significant difference between the two modalities in
treating either large or small tumors. In a well-matched
randomized controlled trial involving 72 patients with HCC,
Shibata et al compared MW ablation with RF ablation.73 This
study found that complete therapeutic effects with RF abla-
tion and MW ablation were 96 and 89%, respectively. Com-
plication rates and rates of residual foci of untreated disease
were also equivalent for both ablation techniques.
Recent studies using improvedMW technology with more
powerful generators have demonstrated improved efficacy by
creating larger ablation zones. Using a newMWdevice with a
2.45-MHz generator, Poggi et al were able to achieve an
overall complete ablation rate of 94.3% in patients with
HCC74; for small HCC (diameter  3 cm), complete necrosis
was obtained in 100%. The rates of complete ablation for the
intermediate (3–5 cm) and large lesions ( 5 cm)were 90 and
69%, respectively.
The evidence supporting MW ablation in the treatment of
metastatic liver tumors is limited. In one of the first studies,
Shibata el al compared laparoscopic-guided MWablation and
surgical resection in patients with metastatic colorectal car-
cinoma in the liver.75 There were no significant differences in
mean survival times, complications, and mean disease-free
intervals between the two groups. Estimated 1-, 2-, and 3-
year survival rates were 71, 57, and 14% for MWablation and
69, 56, and 23% for surgical resection, respectively. Tanaka et
al also reported the efficacy of MW ablation combined with
hepatectomy compared with hepatectomy alone for multiple
bilobar colorectal metastases to the liver.76 Although more
metastases were found in the group with MW ablation and
resection, there were no significant differences in survival
rates or in the pattern of progression between the two groups.
The study concluded that MWablation plus hepatic resection
expanded the indications for operation to treat multiple
bilobar liver metastases, with survival rates similar to those
in less-involved hepatic resection patients.
Radiofrequency Ablation
In RF ablation, a complete electrical circuit is formed across
the patients’ body between a needle electrode and large-
surface ground pads. Rapidly alternating RF current (300–500
KHz) is then generated around an electrode and is propagated
through the tissue, resulting in resistive heating (the Joule
effect). Although initial direct heating occurs within a short
distance of the electrode, a larger ablation zone is eventually
created by thermal conduction, inducing cell death by coagu-
lation necrosis.68
Since RF ablation was first used for HCC66 in 1990, the
technique has been expanding its role in the treatment of
primaryand secondary hepaticmalignancies. In patientswith
small ( 3 cm) tomedium (3–5 cm) sizedHCC, RF ablation has
achieved complete ablation rates of over 80% in a single
treatment session and over 90% in two sessions, with 5-
year survival rates of 40 to 58%. Local progression rates after
complete ablation are 1 to 12%.8,72–74,77–80 Major
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complications include peritoneal hemorrhage, bile duct inju-
ry, abscess, and intestinal perforation,with acceptable rates of
these complications ranging from 0.9 to 5.0%.75,79 In the
treatment of large HCC ( 5 cm), conventional RF ablation
is limited mainly by incomplete ablation, with reported
complete ablation rate of 62% for tumors measuring 5 to
7 cm.81 However, the efficacy is clearly improved when new
devices are used. In a separate study using three bipolar
electrodes and internally cooled electrodes, complete abla-
tion rateswere 81 and 90%, respectively, in patientswith large
HCC.82,83
RF ablation has been compared with PEI in the treatment
of unresectable HCC (2.2–2.9 cm) in several randomized
controlled trials.84 Meta-analysis of these trials showed bet-
ter 1- and 3-year overall survival in patients treated with RF
ablation compared with those treated with PEI. In the RF
ablation group, disease-free survival rates were significantly
better, and disease recurrence rates at the ablation site were
significantly worse than in the PEI group.9–11,85
Cryoablation
Cryoablation is based on the rapid cooling of the cryoprobe by
the Joule–Thompson effect.86 As high-pressure argon gas is
forced through a narrow opening at the distal portion of the
probe and then rapidly expanded to atmospheric pressure,
the temperature of the metallic probe is decreased. This cold
temperature is transferred to surrounding tissue by convec-
tion and conduction. When helium gas passes through the
same system, it causeswarmingof the cryoprobe and thawing
of the tissue.87 Cell death is caused by direct intracellular ice
crystal formation, resulting in physical damage to the plasma
and cytoplasmic organelle membranes.88 During thawing,
intracellular ice crystals continuously grow,maximizing their
biocidal effects.89 If ice crystal formation occurs in the
vascular endothelial cells of blood vessels supplying the
targeted lesion, indirect cellular injury is induced by ischemia
and inflammation.89–91
Cryoablation has been used to treat both primary and
metastatic liver tumors. A multicenter retrospective study of
cryoablation for liver tumors including metastases and HCC
for over 7 years reported that cryoablation for noncolorectal
metastases had significant long-term survival benefit and is a
useful tool for controlling symptoms.92 Recently, Xu et al
evaluated the efficacy of sequential use of TACE and percuta-
neous cryoablation compared with cryoablation alone for
unresectable HCC. A total of 130 patients with intermediate
to large HCC (mean size 4.6 cm) were treated with cryoa-
blation alone.93 During a mean follow-up period of 42  17
months, local recurrence was observed in 23% of patients in
cryoablation-alone group, compared with 11% in cryoabla-
tion plus TACE group (n ¼ 290). The overall 1-, 2-, 3-, 4-, and
5-year survival rates in cryoablation-alone groupwere 72, 57,
47, 39, and 31%, respectively. Although, the 1- and 2-year
survival rates were similar between the two groups, the 4-
and 5-year survival rates were 49 and 39% in sequential
TACE–cryoablation group, higher than those (29 and 23%)
in cryoablation-alone group (p ¼ 0.001). The authors con-
cluded that when TACE is combined with cryoablation, the
efficacy is increased and adverse effects decreased for pa-
tients with unresectable HCC.
In a retrospective study by Adam et al in 2002, a total of 64
patients were treated with either percutaneous cryoablation
(n ¼ 31) or RF ablation (n ¼ 33) for unresectable hepatic
malignancies, and the outcomes were compared between
the two modalities.94 Complication rates were 29% in the
cryoablation group and 8% in RF ablation group. Although
initial treatment success was comparable between the two
groups, the local recurrence rate was higher in patients
treatedwith cryoablation than those treatedwith RF ablation
(53 vs. 18%). Another prospective study comparing intra-
operative cryoablation and RF ablation also demonstrated a
much higher complication rate for cryoablation (41 vs. 3%).95
Major disadvantages of cryoablation include a variable
ablation zone, cold-sink effect from adjacent vessels, and
high complication risk. Local complications are hemorrhage,
cold injury to adjacent organs, biliary injury, and hepatic
parenchymal damage.96 Ice ball formation inside the liver
may cause cracking or shearing of the liver parenchyma,
resulting in major hemorrhage by extension of shearing
injury to major vessels. Late hemorrhage and intrahepatic
abscess can occur by biliary injury. Cryoablation is also
associated with the cytokine-mediated systemic syndrome,
which is known as “cryoshock” and includes fever, tachycar-
dia, and tachypnea. Although cryoablation has some potential
advantages, its utility in the treatment of liver malignancies is
limited mainly due to the higher complication rates, higher
local recurrence rates, and the lack of proven efficacy benefit
compared with other thermal ablation methods.8,97
Conclusion
Although PEI is well established and is the most commonly
used chemical ablation technique for small HCC, due to its
higher local recurrence rates and lower disease-free survival,
RF ablation should be considered the first-line treatment
modality in the treatment of primary and secondary liver
malignancies. However, conventional RF technology is signif-
icantly limited for large HCC ( 5 cm) mainly by incomplete
tumor necrosis. As the technology in RF devices continues to
advance, the efficacy is clearly improved with complete
ablation rates for larger tumors now reported in the 81 to
90% range. In addition, newer technologies are being ad-
vanced that give hope to expanding the types of lesions that
may be treated while potentially reducing the complications.
MW ablation has different underlying mechanisms for gen-
erating heat and is less affected by a heat sink from adjacent
large vessels. Other thermal ablation techniques that also use
heat include laser ablation and HIFU. For small HCC, both
techniques provide good outcomes comparable to that of RF
ablation. IRE is a nonthermal ablation method with lack of a
heat-sink effect, thus enabling better tumor ablationwith less
riskof damage to the adjacent vessels, ducts, or critical organs.
For this reason, interest in IRE continues to increase for
tumors in the pancreas or liver where vital structures can
easily be damaged by heat. Despite some potential
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advantages, the use of cryoablation for liver tumors is still
limited by higher complication rates and the lack of proven
efficacy benefit over other techniques.
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